Treatment of chronic delta hepatitis with lamivudine vs lamivudine plus interferon vs interferon

Basit Öğe Kaydı
dc.contributor.authorYurdaydin, C.
dc.contributor.authorBozkaya, H.
dc.contributor.authorOnder, F. O.
dc.contributor.authorSenturk, H.
dc.contributor.authorKaraaslan, H.
dc.contributor.authorAkdogan, M.
dc.contributor.authorCetinkaya, H.
dc.date.accessioned2024-04-24T17:11:30Z
dc.date.available2024-04-24T17:11:30Z
dc.date.issued2008
dc.departmentDicle Üniversitesien_US
dc.description.abstractChronic delta hepatitis is the most severe form of chronic viral hepatitis for which interferon (IFN) is the only available treatment. In 39 patients (25 were treatment-naive, 14 had previously used IFN), efficacy of 1-year treatment with IFN (9 MU, t.i.w.) or lamivudine (LAM; 100 mg, q.d.) alone was compared with IFN and LAM combination (2 months of LAM to be followed by combination treatment). IFN monotherapy was given only to treatment-naive patients. In both treatment-naive and previous IFN users, end of treatment virological and biochemical responses were similar with IFN-LAM combination and superior to LAM monotherapy (P < 0.05). Improvement in liver histology occurred more often with IFN +/- LAM than with LAM alone (P < 0.05). In treatment-naive patients, combination treatment was not superior to IFN monotherapy. After treatment discontinuation, virological and biochemical response rates decreased in LAM and IFN combination and IFN monotherapy. On treatment virological response at month 6 of treatment predicted sustained virological response. The results of this study suggest that addition of LAM to IFN for the treatment of delta hepatitis is of no additional value and that both treatment modalities are superior to LAM monotherapy.en_US
dc.identifier.doi10.1111/j.1365-2893.2007.00936.x
dc.identifier.endpage321en_US
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.issue4en_US
dc.identifier.pmid18307594
dc.identifier.scopus2-s2.0-40149083430
dc.identifier.scopusqualityQ2
dc.identifier.startpage314en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2893.2007.00936.x
dc.identifier.urihttps://hdl.handle.net/11468/17567
dc.identifier.volume15en_US
dc.identifier.wosWOS:000253631200011
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleTreatment of chronic delta hepatitis with lamivudine vs lamivudine plus interferon vs interferonen_US
dc.titleTreatment of chronic delta hepatitis with lamivudine vs lamivudine plus interferon vs interferon
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu